Microbiome Therapeutics Market: By Product Type (Probiotics, Prebiotics, Synbiotics (Combination of Prebiotics and Probiotics)), By Disease Indication (Digestive-related Disorders (Crohn's Disease, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Others)), Metabolic Disorders (Obesity, Diabetes, Others), Respiratory Infections, Cancer, Immune System, Oral Diseases, Skin Infections, and Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Microbiome Therapeutics Market Size was valued at USD 321.58 million in 2023 and is poised to grow at a CAGR of 22.6% from 2024-2030. A microbiome is the genetic material of all microbes such as bacteria, viruses, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third of bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant in oral health. The market plays a significant role in human health and disease conditions. The global microbiome therapeutics market is still nascent stage, very few products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in terms of microbiome therapeutics market growth, product launches, research, and development activities.

However, bigger players in the microbiome therapeutics market are focused on providing funding, collaborating, and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market is expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to research obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome-mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.

Microbiome Therapeutics Market Key Developments:
  • In July 2016, Series Therapeutics started a clinical trial on its synthetically designed microbiome drug SER-262, to treat Clostridium difficile infection conditions. The study is currently enrolling patients from 22 locations in the U.S. In February 2015, 4D Pharma plc, U.K. based company, acquired Tucana involved in the development of microbiome therapeutics products to treat Irritable Bowel Syndrome (IBS) conditions
  • In January 2016, Takeda Pharmaceuticals Ltd and Enterome entered a strategic drug discovery collaboration to conduct research and development on novel therapeutics that target the microbiome that plays crucial roles in multiple gastrointestinal disease conditions

Global Microbiome Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

22.6%

Largest Market

North-America

Fastest Growing Market

North America
Microbiome Therapeutics Market Dynamics

Increase in evidence about the direct relationship of the microbiome in treating lifestyle diseases, autoimmune diseases such as Crohn inflammatory bowel disease (IBS) conditions are fuelling the growth of the market. Currently, very few drugs are available in the market to treat these disease conditions. Furthermore, microbiome therapeutics are safer than conventional treatments as they are already present in the human body. Microbiome therapeutics possess any side-effects, unlike conventional drugs these factors will have a positive impact on the growth of the market. However, the lack of substantial clinical evidence about the microbiome benefits on human health and regulatory barriers might hamper the growth of the market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Microbiome Therapeutics Market Segmentation

By Product Type
  • Probiotics
  • Prebiotics
  • Synbiotics (Combination of Prebiotics and Probiotics)
By Disease Indication
  • Digestive related disorders
    • Crohn disease
    • Inflammatory Bowel Disease (IBD)
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Metabolic Disorders
    • Obesity
    • Diabetes
    • Others
  • Respiratory Infections
  • Cancer
  • Immune System
  • Oral Diseases
  • Skin Infections
  • Others
By Geography
  • North America,
  • Europe,
  • Asia Pacific,
  • Latin America and
  • Middle East and Africa.

Frequently Asked Questions

The microbiome therapeutics market size was valued at USD 321.58 million in 2022 and is poised to grow at a CAGR of 22.6% from 2024-2030

AB biotics, Enterome, Seres Therapeutics, Vedanta Biosciences, Eligo Bioscience, 4D Pharma plc, Synlogic, TargEDys

North America is the fastest-growing region for microbiome therapeutics market

1.Executive Summary
2.Global Microbiome Therapeutics Market Introduction 
2.1.Global Microbiome Therapeutics Market  - Taxonomy
2.2.Global Microbiome Therapeutics Market  - Definitions
2.2.1.Product Type 
2.2.2.Disease Indication
2.2.3.Region
3.Global Microbiome Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Microbiome Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Microbiome Therapeutics Market  By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Probiotics
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Prebiotics
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Synbiotics (Combination of Prebiotics and Probiotics)
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Microbiome Therapeutics Market  By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Digestive related disorders
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Metabolic Disorders
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Respiratory Infections
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Cancer
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Immune System
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Oral Diseases
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Skin Infections
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Others
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
7.Global Microbiome Therapeutics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America Microbiome Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Product Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Probiotics
8.1.2.Prebiotics
8.1.3.Synbiotics (Combination of Prebiotics and Probiotics)
8.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Digestive related disorders
8.2.2.Metabolic Disorders
8.2.3.Respiratory Infections
8.2.4.Cancer
8.2.5.Immune System
8.2.6.Oral Diseases
8.2.7.Skin Infections
8.2.8.Others
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Microbiome Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Probiotics
9.1.2.Prebiotics
9.1.3.Synbiotics (Combination of Prebiotics and Probiotics)
9.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Digestive related disorders
9.2.2.Metabolic Disorders
9.2.3.Respiratory Infections
9.2.4.Cancer
9.2.5.Immune System
9.2.6.Oral Diseases
9.2.7.Skin Infections
9.2.8.Others
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Microbiome Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Probiotics
10.1.2.Prebiotics
10.1.3.Synbiotics (Combination of Prebiotics and Probiotics)
10.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Digestive related disorders
10.2.2.Metabolic Disorders
10.2.3.Respiratory Infections
10.2.4.Cancer
10.2.5.Immune System
10.2.6.Oral Diseases
10.2.7.Skin Infections
10.2.8.Others
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) Microbiome Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Probiotics
11.1.2.Prebiotics
11.1.3.Synbiotics (Combination of Prebiotics and Probiotics)
11.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Digestive related disorders
11.2.2.Metabolic Disorders
11.2.3.Respiratory Infections
11.2.4.Cancer
11.2.5.Immune System
11.2.6.Oral Diseases
11.2.7.Skin Infections
11.2.8.Others
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America Microbiome Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Probiotics
12.1.2.Prebiotics
12.1.3.Synbiotics (Combination of Prebiotics and Probiotics)
12.2.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Digestive related disorders
12.2.2.Metabolic Disorders
12.2.3.Respiratory Infections
12.2.4.Cancer
12.2.5.Immune System
12.2.6.Oral Diseases
12.2.7.Skin Infections
12.2.8.Others
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Johnson & Johnson
13.2.2.Pfizer Inc.
13.2.3.AB biotics
13.2.4.Enterome
13.2.5.Seres Therapeutics
13.2.6.Vedanta Biosciences
13.2.7.Eligo Bioscience
13.2.8.4D Pharma plc
14. Research Methodology 
15. Appendix and Abbreviations 
  • Johnson & Johnson
  • Pfizer Inc.
  • AB biotics
  • Enterome
  • Seres Therapeutics
  • Vedanta Biosciences
  • Eligo Bioscience
  • 4D Pharma plc
  • Synlogic
  • TargEDys
  • Second Genome
  • LNC research & development
  • Takeda Pharmaceutical Company Ltd
  • PROBI
  • Ritter Pharmaceuticals.

Adjacent Markets